Chemistry Reference
In-Depth Information
Cellular viability (%)
160
MO/DOPE-PEG
2000
/EPA
in presence of BDNF
MO/DOPE-PEG
2000
/EPA without BDNF
140
120
100
80
60
40
20
0
0
2E-05 8E-06
4E-06
8E-07
4E-07
8E-08
4E-08
4E-09
Total lipid concentration (mol/L)
Figure 11.12
Viability of differentiated SH-SY5Y cells treated with BDNF alone or
by MO/DOPE-PEG
2000
/EPA (83/2/15 mol %) NPs in the absence or in the presence of
BDNF (2 ng/ml or 4 × 1 0
− 8
ng/cell). The MTT test was conducted at 37°C. The histo-
grams are presented in a sequence of decreasing total lipid concentrations and expressed
relative to the results obtained with the differentiated cells without neuroprotective
treatment.
(EPA). Hence, the bioactive component EPA was evidenced to potentiate the
effects of BDNF under the investigated conditions.
The relative cellular viability, determined in the presence of BDNF for the
formulation MO/DOPE-PEG
2000
/EPA (83/2/15 mol %) is compared in Figure
11.13 to the viability of cells treated with MO/DOPE-PEG
2000
/OA (83/2/15 mol
%) and DMPC/DOPE-PEG
2000
/EPA (83/2/15 mol %) formulations. In control
experiments, the differentiated SH-SY5Y cells were treated with BDNF
only. It was established that cells treated with the MO/DOPE-PEG
2000
/OA
(83/2/15 mol %) formulation present a lower cell viability compared to those
treated with MO/DOPE-PEG
2000
/EPA (83/2/15 mol %). This confi rms that the
activity of BDNF is potentiated by the EPA and not by other lipids of the
nanocarriers. The maximum cellular viability of 150% was achieved with
the DMPC/DOPE - PEG
2000
/EPA (83/2/15 mol %) NPs formulation at a con-
centration of 4.21
1 0
− 8
M. The phospholipid DMPC appears to participate
in a less signifi cant interaction with the cell membranes and thus displays a
lower cytotoxicity compared to monoolein at the same lipid concentrations.
However, the peptide encapsulation effi ciency in phospholipid nanostructures
could also be lower.
×
Search WWH ::
Custom Search